Licochalcone A / Cyt‑c Cancer Research Results

LCA, Licochalcone A: Click to Expand ⟱
Features:

Licochalcone A - Licorice-Derived Chalcone

Type: Natural chalcone / flavonoid-related phytochemical

Sources: Found primarily in licorice species including Glycyrrhiza inflata and related Glycyrrhiza plants.

Function: Licochalcone A is a bioactive chalcone with anticancer, anti-inflammatory, antioxidant, antimicrobial, and metabolic effects. Reported mechanisms include modulation of PI3K/AKT, MAPK, NF-κB, STAT3, ROS, apoptosis, autophagy, and cell-cycle regulatory pathways.

Cancer: Preclinical studies demonstrate inhibition of cancer-cell proliferation, migration, invasion, and metastasis, together with induction of apoptosis, autophagy, oxidative stress, and cell-cycle arrest. LCA has shown anticancer activity in breast, lung, gastric, colorectal, prostate, liver, ovarian, and other experimental cancer models.

Alzheimer's Disease: Preclinical evidence suggests neuroprotective and anti-inflammatory effects relevant to neurodegeneration, including suppression of oxidative stress and inflammatory signaling, although the Alzheimer's-specific evidence is less developed than the cancer literature.

Licochalcone A — a naturally occurring prenylated chalcone and phenolic phytochemical found principally in licorice species, especially Glycyrrhiza inflata. It is classified as a natural chalcone/flavonoid-related small molecule and is commonly abbreviated LCA, LicA, or Lico A. Its experimental pharmacology is strongly context-dependent: in many cancer models LCA promotes oxidative stress, mitochondrial dysfunction, apoptosis, autophagy, cell-cycle arrest, and suppression of proliferative and inflammatory signaling, whereas in non-malignant injury models it can activate NRF2-dependent antioxidant defenses. Anticancer development remains preclinical.

Primary mechanisms (ranked):

  1. ROS/redox disruption through mitochondrial ROS generation and inhibition of antioxidant systems including TrxR1, promoting oxidative-stress-mediated cancer-cell death.
  2. PI3K/AKT/mTOR suppression, reducing survival signaling and frequently promoting apoptosis and autophagy.
  3. Mitochondrial and endoplasmic-reticulum stress-mediated apoptosis involving mitochondrial membrane depolarization, cytochrome c release, caspase activation, PARP cleavage, and CHOP signaling.
  4. STAT3 suppression, including reduced STAT3 protein/activation and downstream survival and proliferative signaling.
  5. NF-κB and Ras/Raf/MEK pathway suppression, including reduced PD-L1 expression and tumor-cell immune-evasion signaling in experimental models.
  6. Cell-cycle arrest through modulation of cyclins, CDKs, p21/p27, survivin, and related regulatory proteins.
  7. HIF-1α suppression through inhibition of mitochondrial respiration and restoration of intracellular oxygen availability under hypoxic conditions.
  8. Ferroptosis induction in selected models through increased lipid oxidative stress and suppression of the IGF2BP3/MDM2 axis.
  9. Suppression of migration, invasion, angiogenic signaling, and EMT-associated pathways including MAPK/AKT, VEGF, ICAM-1, and related regulators.
  10. NRF2 modulation (context-dependent): NRF2 can be suppressed in some cancer cells, increasing ROS susceptibility, while NRF2 is activated in non-malignant cells and tissues, producing antioxidant and cytoprotective effects.

Bioavailability / PK relevance: Free oral LCA has poor systemic exposure; a rat pharmacokinetic study reported absolute oral bioavailability of approximately 3.3%. Poor aqueous solubility, limited permeability, intestinal first-pass metabolism, glucuronidation, and other metabolic pathways constrain exposure. Formulation materially changes PK: a self-microemulsifying drug-delivery system increased oral bioavailability approximately 2.36-fold in rats, while nanoparticle approaches have produced still larger increases experimentally. LCA also inhibits P-glycoprotein and several CYP enzymes, particularly CYP3A and CYP2C9 in experimental systems, creating a potential drug-interaction concern.

In-vitro vs systemic exposure relevance: Many anticancer experiments use approximately 10–100 μM LCA, with several reported IC50 values in the tens of micromolar range. These concentrations are difficult to reconcile with the low systemic exposure of unformulated oral LCA, so direct translation of conventional cell-culture concentrations to achievable human systemic exposure is uncertain. Delivery systems, local exposure, metabolites, and combination strategies may alter this limitation.

Clinical evidence status: Cancer: preclinical only, with cell-culture and animal xenograft evidence but no established anticancer efficacy in humans. Human exposure evidence is substantially stronger for topical dermatologic/cosmetic use: randomized or prospective studies have evaluated LCA-containing formulations for acne, dermatitis, erythema, and rosacea. LCA is not an established systemic oncology drug. Current translational priorities are exposure optimization, human PK, dose-limiting safety characterization, and controlled oncology trials.

Licochalcone A Cancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS and TrxR1 redox disruption ROS ↑; TrxR1 ↓; GSH ↓ ROS ↓ in oxidative-injury models (context-dependent) P/R Oxidative-stress-mediated cancer-cell death ROS generation is mechanistically central in gastric, colorectal, bladder, ovarian, and other models. ROS scavenging with NAC can substantially attenuate LCA-induced apoptosis.
2 PI3K AKT mTOR survival signaling PI3K ↓; AKT ↓; mTOR ↓ AKT ↑ can contribute to NRF2 protection (context-dependent) R/G Survival inhibition, apoptosis, autophagy Strong recurring cancer mechanism, but signaling direction differs in cytoprotective non-cancer models.
3 Mitochondrial apoptosis Mitochondrial membrane potential ↓; cytochrome c ↑; caspase-9/3 ↑; PARP cleavage ↑ Apoptosis ↓ in several oxidative-injury models R/G Intrinsic apoptotic cell death Often downstream of ROS generation; supported across multiple cancer types.
4 Endoplasmic reticulum stress CHOP GRP78 ↑; CHOP ↑; ER stress ↑; caspase signaling ↑ ER-stress injury ↓ in neuroprotective models R/G ER-stress-mediated apoptosis Reported in bladder, lung, and endometrial cancer; cellular context determines whether ER stress is promoted or suppressed.
5 STAT3 signaling STAT3 ↓; p-STAT3 ↓ Not established R/G Reduced survival and proliferation Demonstrated in ovarian and cholangiocarcinoma models; downstream effects include altered mTOR-associated translation and survival proteins.
6 NF-κB and inflammatory survival signaling NF-κB p65 ↓ NF-κB inflammatory activation ↓ R/G Reduced proliferation, inflammation, migration, and immune-evasion signaling Unlike ROS and NRF2, NF-κB suppression is directionally similar in many malignant and non-malignant inflammatory models.
7 PD-L1 and Ras Raf MEK immune-evasion axis PD-L1 ↓; Ras ↓; NF-κB interaction ↓ Cytotoxic T-cell activity ↑ in co-culture G Reduced tumor immune evasion Colon-cancer experiments showed enhanced T-cell-mediated tumor-cell killing after LCA pretreatment; remains preclinical.
8 Cell-cycle regulation G0/G1 or G2/M arrest ↑; cyclin/CDK signaling ↓ Variable G Cytostatic growth inhibition The arrest point is cell-type-dependent. Cyclin D1, cyclin B1, CDK1, survivin, p21, and related regulators have been implicated.
9 Autophagy and LC3 signaling LC3-II ↑; autophagic flux ↑ Context-dependent G Autophagic response accompanying growth inhibition Prominent in breast and NSCLC models. Autophagy is not consistently required for LCA-induced apoptosis.
10 HIF-1α and mitochondrial respiration Mitochondrial respiration ↓; intracellular O2 ↑; HIF-1α ↓; GLUT1 ↓; PDK1 ↓ Not established P/R Suppression of hypoxic tumor adaptation LCA directly suppresses mitochondrial oxygen consumption, promoting oxygen-dependent HIF-1α degradation under hypoxia.
11 Energy metabolism Mitochondrial ATP production ↓; total ATP ↓ Not established P/R Energetic stress Observed with HIF-1α inhibition. The major demonstrated effect is inhibition of mitochondrial respiration rather than direct blockade of glycolysis.
12 Ferroptosis IGF2BP3 MDM2 IGF2BP3 ↓; MDM2 ↓; lipid ROS ↑; MDA ↑; GSH ↓; ferroptosis ↑ Not established R/G Ferroptotic cell death Demonstrated particularly in acute myeloid leukemia; currently less broadly established than apoptotic mechanisms.
13 MAPK JNK p38 ERK signaling JNK/p38/ERK modulation (model-dependent) ERK ↑ can support NRF2 activation (context-dependent) R/G Apoptosis and stress-response regulation In several cancer models JNK/p38 activation contributes to apoptosis, whereas inhibition of MAPK-associated motility signaling has also been reported.
14 Migration invasion and EMT Migration ↓; invasion ↓; vimentin ↓; EMT signaling ↓ Not established G Reduced metastatic phenotype Includes modulation of MAPK/AKT, adhesion proteins, VEGF, and ICAM-1; evidence is preclinical.
15 NRF2 antioxidant response NRF2 ↓ in selected tumors (context-dependent) NRF2 ↑; HO-1 ↑; GCLC/GCLM ↑ R/G Opposing redox effects according to cellular context Particularly important for interpretation: LCA can suppress NRF2 and increase ROS in some cancers while activating NRF2 and protecting normal tissues from oxidative injury.
16 Chemosensitization Drug-induced apoptosis ↑ (model-dependent) Not established R/G Enhanced anticancer drug response LCA enhanced geldanamycin-induced ROS generation, mitochondrial apoptosis, and caspase activation in ovarian cancer cells; no established clinical combination regimen.
17 Clinical Translation Constraint Systemic exposure limited CYP and transporter interactions possible G Limits translation of high-concentration in-vitro effects Free oral bioavailability in rats has been reported at approximately 3.3%. Poor solubility and first-pass metabolism are important constraints. LCA inhibits CYP3A4, CYP2C9, and P-gp experimentally; formulation can substantially increase exposure.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr



Alzheimer's disease relevance: Licochalcone A now has meaningful disease-specific preclinical evidence rather than only general neuroprotective plausibility. Studies in transgenic AD mouse models report improved cognition together with reduced Aβ burden, reduced neuroinflammation, improved insulin/glucose signaling, inhibition of ER-stress-mediated neuronal apoptosis, and NRF2-associated protection. A 2026 APP/PS1 study reported improved memory, increased synaptic markers, reduced Aβ42 and plaque burden, improved glucose handling, and reduced glial activation after 15 mg/kg/day intraperitoneal LCA for four weeks. A separate transgenic mouse study found inhibition of PERK/eIF2α/ATF4/CHOP ER-stress signaling and neuronal apoptosis. Evidence remains preclinical; there is no established human AD efficacy.

Primary AD mechanisms (ranked):

  1. Reduction of Aβ accumulation and plaque burden.
  2. Suppression of ER-stress-mediated neuronal apoptosis through PERK/eIF2α/ATF4/CHOP inhibition.
  3. Reduction of neuroinflammation and glial activation.
  4. Improvement of brain insulin/glucose signaling and GLUT1-associated metabolic function.
  5. NRF2-dependent antioxidant and neuronal stress protection.
  6. Preservation of synaptic structure and plasticity.
  7. Reduction of tau misfolding and tau-associated oxidative stress in cellular models.

Clinical evidence status: Preclinical. Evidence includes cell studies and multiple transgenic mouse AD models, including disease-specific studies published in 2025 and 2026. Human efficacy, optimal systemic dose, CNS pharmacokinetics, and long-term safety have not been established.

Licochalcone A Alzheimer Mechanisms

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Amyloid beta burden Aβ42 ↓; plaque burden ↓ Reduced amyloid pathology Demonstrated in transgenic mouse AD models; earlier cellular and biochemical work also supports interference with Aβ aggregation.
2 PERK eIF2α ATF4 CHOP ER stress ER stress ↓; CHOP signaling ↓ Reduced neuronal apoptosis Mechanistically supported in triple-transgenic AD mice and primary hippocampal neurons.
3 Neuroinflammation and glial activation Glial reactivity ↓; inflammatory signaling ↓; TREM2 ↓ (model-dependent) Reduced chronic neuroinflammatory burden Consistent with broader LCA suppression of TLR4, NF-κB, and MAPK inflammatory signaling.
4 Brain insulin and glucose signaling Insulin response ↑; Insr ↑; GLUT1 ↑ Improved cerebral metabolic function Reported in APP/PS1 mice together with improved systemic glucose tolerance.
5 NRF2 antioxidant signaling NRF2 ↑; antioxidant defense ↑ Reduced oxidative and ER stress NRF2 inhibition reduces LCA neuroprotective effects in experimental systems, supporting a causal contribution.
6 Synaptic plasticity PSD95 ↑; spinophilin ↑; dendritic spine density ↑ Improved neuronal connectivity and memory-associated plasticity Observed in the 2026 APP/PS1 mouse study together with improvement in behavioral memory tests.
7 Tau proteostasis Tau misfolding ↓; tau-associated ROS ↓ Reduced tau-associated cellular toxicity Supported principally by cellular tau-misfolding models; less developed in vivo than the amyloid and ER-stress evidence.
8 Clinical Translation Constraint Human efficacy not established Limits clinical interpretation Animal studies support CNS activity, but human brain exposure, oral dosing requirements, chronic safety, and disease-modifying efficacy remain unknown.


Cyt‑c, cyt-c Release into Cytosol: Click to Expand ⟱
Source:
Type:
Cytochrome c
** The term "release of cytochrome c" ** an increase in level for the cytosol.
Small hemeprotein found loosely associated with the inner membrane of the mitochondrion where it plays a critical role in cellular respiration. Cytochrome c is highly water-soluble, unlike other cytochromes. It is capable of undergoing oxidation and reduction as its iron atom converts between the ferrous and ferric forms, but does not bind oxygen. It also plays a major role in cell apoptosis.

The term "release of cytochrome c" refers to a critical step in the process of programmed cell death, also known as apoptosis.
In its new location—the cytosol—cytochrome c participates in the apoptotic signaling pathway by helping to form the apoptosome, which activates caspases that execute cell death.
Cytochrome c is a small protein normally located in the mitochondrial intermembrane space. Its primary role in healthy cells is to participate in the electron transport chain, a process that helps produce energy (ATP) through oxidative phosphorylation.
Mitochondrial outer membrane permeability leads to the release of cytochrome c from the mitochondria into the cytosol.
The release of cytochrome c is a pivotal event in apoptosis where cytochrome c moves from the mitochondria to the cytosol, initiating a chain reaction that leads to programmed cell death.

On the one hand, cytochrome c can promote cancer cell survival and proliferation by regulating the activity of various signaling pathways, such as the PI3K/AKT pathway. This can lead to increased cell growth and resistance to apoptosis, which are hallmarks of cancer.
On the other hand, cytochrome c can also induce apoptosis in cancer cells by interacting with other proteins, such as Apaf-1 and caspase-9. This can lead to the activation of the intrinsic apoptotic pathway, which can result in the death of cancer cells.
Overexpressed in Breast, Lung, Colon, and Prostrate.
Underexpressed in Ovarian, and Pancreatic.
Scientific Papers found: Click to Expand⟱
8235- LCA,    Anticancer effects of licochalcones: A review of the mechanisms
- Review, Var, NA
mt-Apoptosis↑, TumAuto↑, TumCMig↓, LC3‑Ⅱ/LC3‑Ⅰ↑, ATG5↑, ATG7↑, p62↑, CHOP/DDIT3↑, ER Stress↑, UPR↑, ATG3↑, Beclin-1/ATG6↑, ATG16L1↑, PERK↑, ATF4↑, ATP↓, Hif1a↓, GLUT1↓, PDK1 / PDPK1↓, Bcl-xL↓, Bcl-2↓, BAD↑, BAX↑, Casp3↑, survivin↓, EGFR↓, ERK↓, Akt↓, mtDam↑, MMP↓, Cyt‑c↑, Casp↑, MDM2↓, CycB/CCNB1↓, CDC2↓, CDC25↓, TumCCA↑, TumCP↓, Wnt↓, β-catenin/ZEB1↓, Sp1/3/4↓, MMP-10↓, MMP3↓, TumCI↓, Imm↑, PD-L1↓, ROS↑, 4E-BP1↓, eIF2α↓, PI3K↓, mTOR↓, p‑cMET↑, Ca+2↑, RUBCN↓, ATG13↑, TSC1↑, TSC2↑, PRAS40↑, PP2A↑, ULK1/ATG1↑, THEM4/CTMP↑, DR5↑, Fas↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, PKCδ↓, P70S6K↓, VEGF↓, angioG↓, HK2↓, Glycolysis↓, TrxR1↓, APAF1↑, cl‑PARP↑, Bax:Bcl2↑, ABCG2↓, BioEnh↑,
8237- LCA,    Role of Licochalcone A in Potential Pharmacological Therapy: A Review
- Review, Var, NA
*other↝, *Inflam↓, *Bacteria↓, *antiOx↑, *AntiP↑, *neuroP↑, *glucose↝, *lipid-P↓, PKCδ↓, P70S6K↓, Akt↓, ER Stress↑, Apoptosis↑, Ca+2↑, PI3K↓, mTOR↓, Casp3↑, Bcl-2↓, Cyt‑c↑, BAX↑, cl‑PARP↑, cycD1/CCND1↑, ROS↑, CHOP/DDIT3↑, ERK↑, p38↑, JNK↓, IAP1↓, XIAP↓, survivin↓, cFLIP↓, RIP1↓, EGFR↓, MET↓, HER2/EBBR2↓, p‑4E-BP1↓, PERK↑, eIF2α↑, PD-L1↓, HK2↓, Glycolysis↓, Sp1/3/4↓, FasL↑, MMP↓, ATP↓, TumAuto↑, WEE1↑, P21↑, CDK1↓, TumCCA↑, TumCMig↓, TumCI↓, ABCG2↓, HSP90↓, T-Cell↑, CD4+↑, CD25+↑, FOXP3↑, Imm↝, *Inflam↓, *NF-kB↓, *NRF2↑, *AntiArt↑,
8243- LCA,    Licochalcone A Inhibits Cellular Motility by Suppressing E-cadherin and MAPK Signaling in Breast Cancer
- in-vitro, BC, MDA-MB-231
Inflam↓, AntiTum↑, TumAuto↑, Sp1/3/4↓, TumCMig↓, MAPK↓, Akt↓, cl‑Casp3↑, cl‑Casp9↑, Bcl-2↓, Cyt‑c↑, TumCP↓, ROS↑, Apoptosis↑, TumCMig↓, TumCI↓, MMP↓, γH2AX↑,
8254- LCA,  Geld,    Licochalcone A enhances geldanamycin-induced apoptosis through reactive oxygen species-mediated caspase activation
- in-vitro, Ovarian, NA
MMP↓, Cyt‑c↑, Casp↑, cl‑PARP1↑, ROS↑, GSH↓, eff↓,
8209- LCA,    Licochalcone A Exerts Anti-Cancer Activity by Inhibiting STAT3 in SKOV3 Human Ovarian Cancer Cells
- in-vitro, Ovarian, SKOV3
tumCV↓, TumCCA↑, ROS↑, MMP↓, Apoptosis↑, cl‑Casp↑, Cyt‑c↑, STAT3↓, TumCP↓, Dose↝, p‑STAT3↓,
8222- LCA,    Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF-κB Signaling Pathways
- in-vitro, CCA, KKU-100 - in-vitro, CCA, KKU-213 - in-vitro, CCA, KKU-214 - in-vitro, CCA, KKU-156 - in-vitro, 0-Reserved, KKU-452
TumCP?, TumCD?, ROS↑, NRF2↓, BAX↑, Cyt‑c↑, TumCMig↓, TumCCA↑, NF-kB↓, STAT3↓, cycD1/CCND1↓, VEGF↓, ICAM-1↓,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ATG13↑, 1,   ATG16L1↑, 1,   RUBCN↓, 1,   THEM4/CTMP↑, 1,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 1,   ULK1/ATG1↑, 1,   WEE1↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

GSH↓, 1,   NRF2↓, 1,   ROS↑, 6,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 2,   CDC2↓, 1,   CDC25↓, 1,   MMP↓, 5,   mtDam↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ATG7↑, 1,   Glycolysis↓, 2,   HK2↓, 2,   PDK1 / PDPK1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 3,   APAF1↑, 1,   Apoptosis↑, 3,   mt-Apoptosis↑, 1,   BAD↑, 1,   BAX↑, 3,   Bax:Bcl2↑, 1,   Bcl-2↓, 3,   Bcl-xL↓, 1,   Casp↑, 2,   cl‑Casp↑, 1,   Casp3↑, 2,   cl‑Casp3↑, 1,   cl‑Casp9↑, 1,   cFLIP↓, 1,   Cyt‑c↑, 6,   DR5↑, 1,   Fas↑, 1,   FasL↑, 1,   IAP1↓, 1,   JNK↓, 1,   MAPK↓, 1,   MDM2↓, 1,   p38↑, 1,   RIP1↓, 1,   survivin↓, 2,   TumCD?, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,   Sp1/3/4↓, 3,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 2,   eIF2α↓, 1,   eIF2α↑, 1,   ER Stress↑, 2,   HSP90↓, 1,   PERK↑, 2,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG3↑, 1,   ATG5↑, 1,   Beclin-1/ATG6↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   p62↑, 1,   TumAuto↑, 3,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 2,   cl‑PARP1↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   cycD1/CCND1↑, 1,   P21↑, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   p‑4E-BP1↓, 1,   p‑cMET↑, 1,   ERK↓, 1,   ERK↑, 1,   mTOR↓, 2,   P70S6K↓, 2,   PI3K↓, 2,   STAT3↓, 2,   p‑STAT3↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 2,   MET↓, 1,   MMP-10↓, 1,   MMP3↓, 1,   PKCδ↓, 2,   TSC1↑, 1,   TumCI↓, 3,   TumCMig↓, 5,   TumCP?, 1,   TumCP↓, 3,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   ATF4↑, 1,   EGFR↓, 2,   Hif1a↓, 1,   VEGF↓, 2,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD25+↑, 1,   CD4+↑, 1,   FOXP3↑, 1,   ICAM-1↓, 1,   Imm↑, 1,   Imm↝, 1,   Inflam↓, 1,   NF-kB↓, 1,   PD-L1↓, 2,   T-Cell↑, 1,  

Protein Aggregation(tgid=19) ⓘ

PP2A↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 2,   BioEnh↑, 1,   Dose↝, 1,   eff↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 2,   HER2/EBBR2↓, 1,   PD-L1↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   PRAS40↑, 1,  
Total Targets: 122

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiArt↑, 1,   AntiP↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   lipid-P↓, 1,   NRF2↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

glucose↝, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 2,   NF-kB↓, 1,  

Functional Outcomes(tgid=23) ⓘ

neuroP↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 11

Scientific Paper Hit Count for: Cyt‑c, cyt-c Release into Cytosol
6 Licochalcone A
1 Geldanamycin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:447  Target#:77  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page